PILOT OF BUTHIONINE SULFOXIMINE WITH MELPHALAN IN NEUROBLASTOMA

神经母细胞瘤的治疗失败可能与获得性烷化剂有关 烷化剂的抗药性和抗肿瘤作用可能会增强 用药物丁硫氨酸亚磺胺耗尽谷胱甘肽 (BSO)。本研究将评价其药代动力学和临床应用。 联用(BS0)和马法兰对儿童的毒性反应 神经母细胞瘤。这项研究的另一个目标是记录GSH 外周血淋巴细胞、正常骨髓和神经母细胞瘤的耗竭 在骨髓中发现的细胞。

Treatment failure in neuroblastoma likely involves acquired alkylator resistance and the anti-tumor effect of alkylating agents may be increased by depletion of glutathione (GSH) with the drug buthionine sulfoximine (BSO). This study will evaluate the pharmacokinetics and clinical toxicities of the combination of (BS0) and melphalan in pediatric patients with neuroblastoma. An additional goal of this study is to document GSH depletion in peripheral blood lymphocytes, normal marrow and neuroblastoma cells found in the bone marrow.